Integrin Linked Kinase and Ovarian Cancer Metastasis

整合素连接激酶与卵巢癌转移

• 批准号: 8125606
• 负责人: Lana Y Bruney
• 金额: $ 2.83万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8125606
• 关键词: Address; Adhesions; Affect; American; Anoikis; Biological Process; Cancer cell line; Cell Line; Cells; Cessation of life; Clinical Management; Collagen; Cytoplasmic Tail; Data; Diagnosis; Disease; Doctor of Philosophy; Dominant-Negative Mutation; Drops; Epithelial Cells; Epithelial ovarian cancer; Event; Goals; Greater sac of peritoneum; Human; In Vitro; Integrin Binding; Integrin-mediated Cell Adhesion Pathway; Integrins; Malignant Neoplasms; Malignant neoplasm of ovary; Mediating; Metastatic Lesion; Metastatic to; Modeling; Molecular; Neoplasm Metastasis; Newly Diagnosed; Ovarian Carcinoma; Phosphorylation; Phosphotransferases; Play; Post-Translational Protein Processing; Primary Neoplasm; Process; Proliferating; Proteins; Research Training; Role; Secondary Lesion; Survival Rate; Tissue Microarray; Tissues; Tumor Tissue; Western Blotting; Woman; cancer cell; cancer diagnosis; design; human MMP14 protein; in vivo Model; inhibitor/antagonist; integrin-linked kinase; interstitial; intraperitoneal; pre-clinical; pre-doctoral; research study; therapeutic target

DESCRIPTION (provided by applicant): The immediate objectives of this application are to provide high level pre-doctoral research training to Ms. Lana Bruney and to increase the diversity of the scientific workforce. Epithelial ovarian cancer (EOC) is the fifth leading cause of overall cancer death among American women. In 2008, 15,520 deaths were directly attributed to EOC, and an additional 21,650 cases were diagnosed. When EOC is diagnosed prior to metastatic dissemination, the overall 5 year survival rate is 93%; however, over 75% of women with EOC are diagnosed with metastasis already present, dropping the survival rate to less than 20%. The process of EOC metastasis is unique in that epithelial cells detach from the primary tumor and are shed into the peritoneal cavity as single cells and multicellular aggregates (MCA), that adhere intraperitoneally. These MCAs undergo localized invasion into the interstitial collagen-rich submesothelial matrix, where they proliferate to anchor secondary lesions. The exact mechanism that controls the transition from detached cells to peritoneally anchored metastatic lesions is still unknown. We have made initial steps toward elucidating this mechanism. 21 integrin activation is a key event in ovarian carcinoma metastatic dissemination and regulates expression of several gene products involved in metastasis, including membrane type 1 matrix metalloproteinase (MT1- MMP). Our studies on the function of MT1-MMP cytoplasmic tail phosphorylation have uncovered a role for MT1-MMP in MCA formation and invasion. Integrin-linked kinase (ILK), a 21 integrin cytoplasmic domain interactor, is activated by integrin-mediated cell adhesion. ILK activation has been shown to regulate several biological processes that suppress anoikis and promote invasion, two key events in ovarian cancer metastasis. The goal of this proposal is to address the central hypothesis that integrin-linked kinase (ILK) activity plays a role in ovarian cancer intraperitoneal metastasis. Proposed aims will characterize the expression of integrin linked kinase (ILK) in ovarian cancer cells and tissues; examine the potential role of ILK in the post- translational modification of MT1-MMP and investigate the contribution of ILK activation to in vitro and in vivo models of ovarian cancer metastasis. Taken together, the results from these experiments will provide key preclinical data necessary to evaluate ILK as a potential therapeutic target for clinical management of EOC metastasis. PUBLIC HEALTH RELEVANCE: Epithelial ovarian cancer (EOC) will affect 1 out of every 69 women born in the US today. Currently 80% of women newly diagnosed with EOC already have metastatic disease. The immediate objective of these studies is to provide high quality PhD research training to Ms. Lana Bruney and to promote diversity in the scientific workforce. The long-term goal of these studies is to gain a molecular level understanding of EOC metastasis to design strategies to more effectively target metastatic disease.

描述(由申请人提供)：该申请的直接目标是为Lana Bruney女士提供高水平的博士前研究培训，并增加科学劳动力的多样性。上皮性卵巢癌(EOC)是美国女性癌症死亡的第五大原因。2008年，15,520例死亡直接归因于平等机会，另有21,650例被诊断。当卵巢癌在转移之前被诊断时，总的5年生存率为93%；然而，超过75%的卵巢癌妇女被诊断为已经存在转移，使生存率降至不到20%。EOC的转移过程是独特的，即上皮细胞从原发肿瘤中分离出来，以单细胞和多细胞聚集体(MCA)的形式进入腹膜腔，并在腹膜内粘连。这些MCA局部侵入富含胶原的间皮下基质，在那里它们增殖以锚定继发性病变。控制从分离的细胞到腹膜锚定的转移灶的确切机制仍不清楚。我们已经在阐明这一机制方面取得了初步进展。21整合素活化是卵巢癌转移转移过程中的一个关键事件，并调节多种参与转移的基因产物的表达，其中包括膜型1基质金属蛋白酶(MT1-MMPs)。我们对MT1-MMP胞浆尾部磷酸化功能的研究揭示了MT1-MMPs在MCA的形成和侵袭中的作用。整合素连接的激酶(ILK)是一种21-整合素胞浆结构域相互作用蛋白，由整合素介导的细胞黏附激活。ILK的激活已被证明可以调节抑制失巢凋亡和促进侵袭的几个生物学过程，这是卵巢癌转移中的两个关键事件。这项建议的目的是为了解决整合素连接激酶(ILK)活性在卵巢癌腹膜内转移中发挥作用的中心假设。本研究旨在研究整合素连接蛋白激酶(ILK)在卵巢癌细胞和组织中的表达，研究ILK在MT1-MMPs翻译后修饰中的潜在作用，并探讨ILK激活在卵巢癌体外和体内转移模型中的作用。综上所述，这些实验的结果将提供关键的临床前数据，以评估ILK作为临床治疗EOC转移的潜在靶点。 与公共卫生相关：如今，美国每69名出生的女性中就有一名患有上皮性卵巢癌。目前，80%的新诊断为EoC的女性已经有转移性疾病。这些研究的直接目标是为Lana Bruney女士提供高质量的博士研究培训，并促进科学工作者的多样性。这些研究的长期目标是获得对卵巢癌转移的分子水平的了解，以设计更有效地针对转移疾病的策略。